There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Werewolf Therapeutics (HOWL – Research Report) and AbbVie (ABBV – Research Report) with bullish sentiments.
Werewolf Therapeutics (HOWL)
In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Werewolf Therapeutics, with a price target of $15.00. The company’s shares closed last Friday at $5.41, close to its 52-week high of $5.59.
According to TipRanks.com, Maldonado is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Werewolf Therapeutics with a $15.00 average price target.
See today’s best-performing stocks on TipRanks >>
AbbVie (ABBV)
According to TipRanks.com, Shibutani is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbbVie with a $175.07 average price target, a 3.3% upside from current levels. In a report issued on February 2, Truist Financial also maintained a Buy rating on the stock with a $180.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HOWL:
